The effects of cell-free extracts derived from probiotic strains Bifidobacterium bifidum and Lactobacillus reuteri on the proliferation and biofilm formation by Lactobacillus reuteri in vitro

Knysh, O. V.

doi:10.14739/2310-1210.2019.6.186711

Cited by 3 publications

(2 citation statements)

References 19 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Застосування біологічно активних дериватів у складі безклітинних пробіотичних продуктів покликане вирішити проблему небажаних ефектів і недостатньої ефективності клітинних пробіотиків [4,15]. Нашими попередніми дослідженнями встановлено, що безклітинні екстракти, отримані шляхом дезінтеграції пробіотичних бактерій термоциклюванням з наступним культивуванням у власних дезінтегратах, здатні стимулювати проліферацію і біоплівкоутворення пробіотичних бактерій та пригнічувати ріст потенційних патогенів [7,8,9].…”

Section: вступunclassified

Adhesive Properties of Bacteria Under the Influence of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938i Cell-Free Extracts

Knysh

Kolpak

Pogorila

et al. 2020

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

Increasing in the adhesive potential of probiotic bacteria on the one hand and weakening the adhesive ability of the pathobionts on the other is a pathogenetically based approach in the fight against intestinal infectious diseases and intestinal dysbiosis. At present postbiotic products are considered as one of the most promising means of influencing the intestinal microbiota. The aim of the work was to study the effect of cell-free extracts containing derivatives of Bifidobacterium bifidum 1 and Lactobacillus reuteri DSM 17938 on the adhesive properties of probiotic (L. reuteri DSM 17938 and B. bifidum 1) and opportunistic bacteria (Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922). Four cell-free extracts were investigated: L – obtained from the L. reuteri disintegrate; ML – obtained from the L. reuteri culture, cultivated in its own disintegrate; B – obtained from the B. bifidum disintegrate; MB – obtained from the B. bifidum culture, cultivated in its own disintegrate. The effect of cell-free extracts on the adhesive properties of microorganisms was studied by using Brilis method. ML, MB, and B extracts were found to be able to significantly increase the adhesive potential of B. bifidum and L. reuteri. Under their influence adhesion index calculated for bifidobacteria increased by 41.1 % (ML), 41.5 % (MB) and 50.6 % (B), and the microorganism adhesion index calculated for lactobacilli increased by 30.77 % (ML), 44.45 % (MB) and 44.97 % (B). Both studied probiotic bacteria moved up from the category of «moderately adhesive» into the category of «strongly adhesive» with microorganism adhesion index > 4.0. Lactobacilli also became «strongly adhesive» under the influence of L extract, while microorganism adhesion index increased by 37.9 %. Among the studied extracts, only L extract caused a significant increase in the adhesion index of the S. aureus test culture. The other extracts caused minor changes in the adhesive potential of the test cultures. Under their influence, there was a tendency to increase or decrease the adhesive ability of bacteria. Under the influence of MB extract, the S. aureus test culture passed from the «strongly adhesive» category to the «moderately adhesive» category, and the E. coli test culture transferred from the «moderately adhesive» category to the «weakly adhesive» category. The data obtained are of great importance when developing new metabiotics based on the B. bifidum 1 and L reuteri DSM 17938 probiotic strains derivatives.

show abstract

Section: вступunclassified

Adhesive Properties of Bacteria Under the Influence of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938i Cell-Free Extracts

Knysh

Kolpak

Pogorila

et al. 2020

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

show abstract

“…Для налагодження промислового виробництва постбіотичних засобів необхідними є науково і економічно обґрунтований спосіб отримання пробіотичних похідних та достатня доказова база їх біологічної активності, лікувальної ефективності та безпеки. Нами були розроблені оригінальні способи одержання дериватів пробіотичних штамів Bifidobacterium bifidum 1 і Lactobacillus reuteri DSM 17938 та в експериментах in vitro отримані дані, що демонструють високу інгібіторну щодо патобіонтів, стимуляторну щодо пробіотичних бактерій та імуномодуляторну активність дериват-вмісних безклітинних екстрактів (БКЕ) [12,13,14,15]. Зважаючи на те, що активність in vitro не можна ототожнювати з активністю in vivo, перед нами постало завдання дослідити ефективність застосування БКЕ при інфекційному процесі та дисбіозі у лабораторних тварин.…”

unclassified

Application Efficiency of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938 Cell-Free Extracts in Vivo

Knysh

Marina

Polianska

et al. 2020

RS Global - Science Review

View full text Add to dashboard Cite

Insufficient efficiency and safety of cellular probiotics encourages the search for new effective means of correction of microecological disorders. Most of the beneficial effects of probiotics are due to the biological activity of their structural components and metabolites. Recently, great hope is pinned on postbiotic products as a means of restoring the balance of intestinal microbial populations. The data obtained in this experimental study demonstrate the ability of cell-free extracts from Bifidobacterium bifidum 1 and Lactobacillus reuteri DSM 17938 cultures, cultivated in their own disintegrates supplemented with ascorbic acid, to provide anti-infection protection and correct microecological disturbances at modeling an infectious process against a background of antibiotic-induced dysbiosis in mice. The beneficial effects of cell-free extracts showed up in the acceleration of the pathogen elimination and an increase in the number of representatives of the positive intestinal microbiota. The results of the study justify the need for further clinical trials to determine the therapeutic efficacy of cell-free extracts when included in the protocols of dysbiosis treatment.

show abstract

135 Years of History and Modernity of the State Institution «i. I. Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine»

Minukhin¹,

Sklyar²,

Medvedovska³

et al. 2021

Journal NAMSU

View full text Add to dashboard Cite

The article is devoted to the results of a retrospective study of the historical path of formation and development of scientific research in State Institution «I. I. Mechnikov Institute of Microbiology and Immunology of the NAMS of Ukraine». The Institute as a scientific institution of anti-epidemic profile was founded in May 1886. At the beginning of the last century, the Institute turned into a major scientific and practical center of pre-revolutionary Russia for the fight against infectious diseases. Already in 1913-1914 the Institute produced 6 types of sera and 7 vaccines. In 1920 the Institute was nationalized, became a state institution and received the name of the Bacteriological Institute, and in 1922 – the First Ukrainian Sanitary-Bacteriological Institute. The Institute was the first in the Soviet Union to begin the production of BCG and became one of the pioneers of the introduction of bacteriophage in the treatment and prevention of intestinal infections: dysentery, typhoid fever, cholera. From 1921 to 1940, the Institute produced more than 40 names of various drugs in an amount exceeding the previous 20 years by more than thirty times. In addition, the Institute currently produces the following serum: diphtheria, scarlet fever, dysentery, meningococcal, pneumococcal, streptococcal, staphylococcal, tetanus, botulinum and 4 gangrenous sera. Since the beginning of the war, the Institute has been evacuated first to Stalingrad and then to Chkalov. During the evacuation, the Institute continues to produce bacteriological preparations. From 1941 to 1945 the release of vaccines and serums amounted to 400% of the pre-war level, only in 1942 110 thousand wounded soldiers received serum against gas gangrene, more than 120 thousand soldiers received tetanus serum. After re-evacuation to Kharkiv, the Institute continued to work on the production of vaccines and serums and, starting in 1944, began the production of smallpox detritus, measles serum and typhus vaccine. At that time, in the laboratory of V. S. Derkach, the antibiotic pyocyanin (or sanazine) was studied and a method for its biosynthesis was developed, and together with the Academy of Sciences of the Ukrainian SSR, its new homologues were synthesized. Also in the laboratory after the war, neocide a drug against cancer was created. The problems of epidemiology at the Institute were developed by the outstanding microbiologist V. M. Zhdanov. From 1946 to 1950 V. M. Zhdanov headed the virological laboratory, and since 1948 – the Kharkov Institute of Microbiology and Epidemiology named I. I. Mechnikov. In 1950, a laboratory for the production of anti-influenza drugs was organized, and a year later, the study and improvement of dry polytype therapeutic and prophylactic anti-influenza serum began. The collection of mycobacterial phages, collected by Professor L. A. Kosobutsky, Doctor of Medical Sciences, was one of the three largest in the world. At the Institute, on the basis of fish oil, the drug «ektericide» was developed. V. L. Nadtoka became the founder of a new scientific direction for the development and use of antimicrobial preparations of plant origin. Under the leadership of V. L. Nadtoka developed dosage forms of the drug chlorophyllipt, which are introduced into production and clinical practice in Ukraine. Now the Institute is a methodological center for the development of theoretical provisions and practical use of laboratory diagnostic methods, anti-epidemic measures, treatment and prevention of infectious diseases, advanced training of bacteriologists, virologists, epidemiologists and other specialists. Currently, on the basis of the Institute, there are a number of divisions of industry-wide importance that coordinate scientific and methodological work in important areas of infection control: the Center for Specific Indication of Biological Pathogenic Agents, the Republican Reference Laboratory of Pathogens of Anaerobic Infections, the Laboratory of New and Little-Studied Infectious Diseases. In general, the staff of the Institute over the years of its existence has developed and introduced into production about 60 different vaccines, sera and other therapeutic and diagnostic immunobiological preparations. The Institute has developed drugs against 21 infections. In addition to immunobiological drugs, the Institute has developed and introduced a number of antimicrobial drugs, among which the most famous are chlorophyllipt, decamethoxin, ektericide, eucavan and others. Keywords: history of science, I.Mechnikov Institute of Microbiology and Immunology, bacteriological preparations, vaccines, serums, bacteriophages, antimicrobial agents, chlorophylipt

show abstract

The effects of cell-free extracts derived from probiotic strains Bifidobacterium bifidum and Lactobacillus reuteri on the proliferation and biofilm formation by Lactobacillus reuteri in vitro

Cited by 3 publications

References 19 publications

Adhesive Properties of Bacteria Under the Influence of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938i Cell-Free Extracts

Adhesive Properties of Bacteria Under the Influence of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938i Cell-Free Extracts

Application Efficiency of Bifidobacterium Bifidum 1 and Lactobacillus Reuteri DSM 17938 Cell-Free Extracts in Vivo

135 Years of History and Modernity of the State Institution «i. I. Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine»

Contact Info

Product

Resources

About